{
  "success": false,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    6,
    7,
    8,
    9,
    11,
    12,
    13,
    15,
    16,
    17,
    18,
    19,
    20,
    21,
    22,
    23,
    26,
    27,
    28,
    29
  ],
  "modelUsed": "gemini-3-flash-preview",
  "rawResponse": [
    {
      "studyDesign": {
        "type": "Interventional",
        "trialIntentTypes": [
          "Treatment"
        ],
        "blinding": {
          "schema": "Double Blind",
          "maskedRoles": [
            "Subject",
            "Investigator"
          ]
        },
        "randomization": {
          "type": "Randomized",
          "allocationRatio": "2:2:1:1",
          "stratificationFactors": [
            "Extent of psoriasis (>= 3% BSA or < 3% BSA)",
            "Current use of at least 1 DMARD",
            "Number of prior failed biologic DMARDs (1 vs > 1)"
          ]
        },
        "controlType": "Placebo",
        "therapeuticAreas": [
          "Rheumatology"
        ]
      },
      "arms": [
        {
          "name": "Group 1: upadacitinib 15 mg QD",
          "type": "Experimental Arm",
          "description": "Subjects receive upadacitinib 15 mg once daily for the duration of the study.",
          "isTitration": false
        },
        {
          "name": "Group 2: upadacitinib 30 mg QD",
          "type": "Experimental Arm",
          "description": "Subjects receive upadacitinib 30 mg once daily. Note: Per Amendment 8, subjects on 30mg will be switched to 15mg at their next visit.",
          "isTitration": false
        },
        {
          "name": "Group 3: Placebo followed by upadacitinib 15 mg QD",
          "type": "Experimental Arm",
          "description": "Subjects receive placebo for the first 24 weeks, then switch to upadacitinib 15 mg once daily.",
          "isTitration": false
        },
        {
          "name": "Group 4: Placebo followed by upadacitinib 30 mg QD",
          "type": "Experimental Arm",
          "description": "Subjects receive placebo for the first 24 weeks, then switch to upadacitinib 30 mg once daily.",
          "isTitration": false
        }
      ],
      "cohorts": [
        {
          "name": "Bio-IR",
          "characteristic": "Subjects with moderately to severely active Psoriatic Arthritis who have an inadequate response to at least one biologic DMARD"
        }
      ],
      "epochs": [
        {
          "name": "Screening",
          "description": "Up to 35 days"
        },
        {
          "name": "Period 1 (Weeks 0-24)",
          "description": "Double-blind, placebo-controlled parallel-group treatment"
        },
        {
          "name": "Period 1 (Weeks 24-56)",
          "description": "Blinded treatment where placebo subjects switch to active upadacitinib"
        },
        {
          "name": "Period 2",
          "description": "Long-term extension (up to 3 years total) initially blinded then open-label"
        },
        {
          "name": "Follow-up",
          "description": "30-day follow-up call or visit"
        }
      ]
    }
  ]
}